ARNA Genomics
ARNA Genomics is a pre-commercial US-headquartered biotech developing multiomics liquid biopsy tests for early cancer detection, with its flagship ARNA Breast test analyzing six oncospecific genes from a blood sample to detect breast cancer at >90% accuracy, targeting hospitals and research institutions ahead of FDA and CE-Mark approvals.
- Company typePrivate
- Founded2013
- HeadquartersMoscow, Russia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What ARNA Genomics does
ARNA Genomics US Inc. is a private biotechnology company founded in 2013 (originally as LLC BIOMARKER-RU in Russia) that develops multiomics liquid biopsy tests for early-stage cancer detection. Its flagship product, ARNA Breast, analyzes free-circulating DNA fragments and plasma enzyme activity from a 10ml blood sample to detect six oncospecific genes associated with breast cancer, reporting >90% accuracy in early-stage detection. A proof-of-concept study at Sechenov First Moscow State Medical University on 80 biosamples showed 100% sensitivity, 85-91% specificity, and 100% negative predictive value, with broader blinded studies covering 1,160 patients in Russia and over 600 patients tested with the technology. The underlying platform is patented (applications filed across USA, EU, India, Israel, China, Korea, and Eurasia) and is positioned to extend into tests for lung, liver, pancreatic, colon, ovarian, and prostate cancers.
The company is led by CEO/Founder Egor Melnikov and CSO Anatoly Melnikov, with Dr. Charles R. Cantor (US National Academy of Sciences, founder and former CSO of Sequenom) serving as Scientific Board Chairman and shareholder. ARNA's go-to-market is enterprise-led, targeting hospitals, healthcare systems, and research institutions through direct partnerships (Mayo Clinic, Hoag Memorial Hospital, MNCCTN, Sechenov University, Medical Valley) and clinical trials in the US (New Jersey) and Germany (Mannheim). The commercial model is sale/licensing of in vitro diagnostic tests, with no public pricing disclosed; revenue generation is contingent on securing FDA LDT status in the US and CE-Mark in the EU, both of which are in progress.
ARNA is headquartered in Aliso Viejo, California, with a European office in Forchheim, Germany (opened February 2019 via Medical Valley's Softlanding Program) and a registered office in Dover, Delaware. The company has raised $3.5M in a Series A led by Xploration Capital (September 2020), with Iskra Ventures also listed as an investor, and is supported by Skolkovo Foundation and various Russian state-backed innovation programs. To date, the company is pre-commercial with no disclosed revenue, and its near-term value creation hinges on successful regulatory milestones and clinical validation of ARNA Breast.
ARNA Genomics firmographics
Firmographics- Name
- ARNA Genomics
- Legal name
- ARNA Genomics US Incorporated
- Website
- https://arna.bio
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ARNA Genomics is a pre-commercial US-headquartered biotech developing multiomics liquid biopsy tests for early cancer detection, with its flagship ARNA Breast test analyzing six oncospecific genes from a blood sample to detect breast cancer at >90% accuracy, targeting hospitals and research institutions ahead of FDA and CE-Mark approvals.
- Ownership category
- akta.pro rank
ARNA Genomics industry classification
Industry- Product category
- Early Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where ARNA Genomics is headquartered
LocationHeadquarters
- HQ city
- Moscow
- HQ country
- Russia
- HQ region
- Europe
Offices4 records
Markets served
ARNA Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel
Revenue model
- Diagnostic Testing Services: Revenue from providing liquid biopsy diagnostic tests for cancer detection, primarily ARNA Breast test for breast cancer screening and early detection.
- In Vitro Diagnostic Tests: Sale of in vitro diagnostic tests for early breast cancer detection based on combined analysis of oncogene fragments in cell-free DNA and plasma enzyme activity.
- Technology Licensing: ARNA technology platform allows development of tests for multiple cancers (lung, liver, pancreas, colon, ovarian, prostate). Future revenue from licensing technology and tests to other markets.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
ARNA Genomics product offering
Product offeringCore offering
ARNA Genomics develops and sells multiomics liquid biopsy diagnostic tests for early cancer detection, with its flagship ARNA Breast test analyzing free-circulating DNA in blood plasma to detect 6 oncospecific genes for breast cancer screening. The technology is delivered to healthcare providers, hospitals, and research institutions through clinical trials and medical partnerships, requiring only a 10ml blood sample and achieving >90% accuracy in early-stage cancer detection.
Product overview
ARNA Genomics offers a multiomics liquid biopsy technology platform for early cancer diagnostics. The core product is the ARNA Breast test, which detects breast cancer through analysis of 6 oncospecific genes in free-circulating DNA and plasma enzyme activity. This flagship product achieved >90% accuracy in proof-of-concept studies. The platform was originally developed based on ARNA-1, the company's first general cancer marker. The company is also developing tests for stomach, pancreatic, ovarian, and other cancers using the same technology foundation.
Differentiator
Problem solved
Functional benefit
Products and services
- ARNA Breast Multiomics liquid biopsy test for early breast cancer detection that analyzes free-circulating DNA (sc-DNA) in blood plasma to detect 6 oncospecific genes and measures plasma enzyme activity. Achieves >90% accuracy in detecting early-stage breast cancer with just 10ml of venous blood. Targeted at healthcare providers, hospitals, and clinical research institutions performing cancer screening.
- ARNA-1 First cancer marker developed within the ARNA project that determines whether a person has an oncological disease without tumor localization. Serves as the foundational technology for subsequent specific cancer tests including ARNA Breast.
- ARNA Technology Platform (Multi-Cancer Diagnostics) Multiomics liquid biopsy technology platform that enables development of diagnostic tests for multiple cancer types including lung, liver, pancreas, colon, ovarian, and prostate. Features a patented method of amplifying freely circulating DNA directly from blood plasma without prior isolation, combined with analysis of specific gene combinations. Targeted at pharmaceutical and biotechnology partners for licensing and development.
Quantifiable outcome
- >90% accuracy for early stage breast cancer detection
- +5 more outcomes
Companies that use ARNA Genomics
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
ARNA Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
ARNA Genomics partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, strategic and minor.
- Sechenov First Moscow State Medical UniversitycoreConducted proof-of-concept study of ARNA Breast test on 80 biosamples. Professor M.I. Sekacheva presented results at Russian Oncological Congress. Study achieved 100% sensitivity and 85% specificity.
- Medical ValleycoreMedical Valley ecosystem partner. Opened European office in Forchheim, Bavaria as part of Softlanding Program. Working towards CE mark registration for ARNA Breast test for entire EU market.
- Charles R. CantorcoreDr. Charles R. Cantor joined as shareholder and Board member. World-renowned scientist, member of US National Academy of Sciences, inventor of pulse field gel electrophoresis, author of 400+ articles and 54 US patents.
- Mayo ClinicstrategicMedical research collaboration partner in diagnostics development for cancer detection.
- Hoag Memorial Hospital PresbyterianstrategicMedical partnership for breast cancer diagnostics research and development.
- University Lab PartnersminorResearch partnership with University Lab Partners for biotechnology research collaboration.
- Soka UniversityminorAcademic partnership for research and development in biotechnology.
- University of MannheimminorAcademic partnership with University of Mannheim for biotechnology research.
- MNCCTN (Minnesota North Central Cancer Treatment Group)minorCancer research network partnership for clinical research collaboration.
- Skolkovo FoundationstrategicSupported by Skolkovo Foundation for startup development and innovation in biotechnology.
Scale indicators6 records
Recent moves6 records
Expansion highlights7 records
ARNA Genomics competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
ARNA Genomics social profiles
Digital presenceARNA Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARNA Genomics leadership team
Management profileNumber of profiles
Profiles8 records
ARNA Genomics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARNA Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARNA Genomics
What does ARNA Genomics do?
ARNA Genomics develops and sells multiomics liquid biopsy diagnostic tests for early cancer detection, with its flagship ARNA Breast test analyzing free-circulating DNA in blood plasma to detect 6 oncospecific genes for breast cancer screening. The technology is delivered to healthcare providers, hospitals, and research institutions through clinical trials and medical partnerships, requiring only a 10ml blood sample and achieving >90% accuracy in early-stage cancer detection.
Is ARNA Genomics a public or private company?
ARNA Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was ARNA Genomics founded?
ARNA Genomics was founded in 2013. It employs 11 to 50 people.
Where is ARNA Genomics based?
ARNA Genomics is headquartered in Moscow, Russia, in the Europe region.
How does ARNA Genomics make money?
Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are in Vitro Diagnostic Tests and technology Licensing.
Does ARNA Genomics have an API?
No public API is recorded for ARNA Genomics.
What industry is ARNA Genomics in?
ARNA Genomics's product category is Early Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 8071.